Clinical trials: Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Carcinoma, Squamous Cell, Head and Neck Neoplasms
Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
The purpose of this research study is to determine whether and when patients with human papilloma virus positive squamous cell cancer of the oropharynx treated with radiation and chemotherapy clear their human papilloma virus…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT02045186
- Testing
- Assessment of Oral HPV Infection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Oropharyngeal Squamous Cell Carcinoma
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection.
- Trial name
- De-ESCALaTE (NCT01874171)
- Testing
- Cisplatin, Cetuximab
- Where
- 33 sites in Ireland, Netherlands and 1 more
- Volunteers
- 334 people
- Sponsor
- University of Warwick
Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
This is a minimal risk feasibility study involving the analysis of patient samples and does not involve any therapeutic intervention.
- Trial name
- ROMA LA-OPSCC (NCT03759730)
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma.
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT04564989
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous…
- Trial name
- NCT07133958
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhujiang Hospital
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Oropharyngeal Squamous Cell Carcinoma
A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
Inclusion of new biomarkers to improve the personalized treatment approach for HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC) patients is urgently needed.
- Trial name
- NCT06138483
- Where
- 5 sites in Italy
- Volunteers
- 267 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Oropharynx Cancer, Oropharynx Cancer, Metastatic
Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?
This study investigates if longitudinal analyses of cell-free HPV-DNA in blood samples can be utilized to detect recurrence in patients diagnosed and treated for HPV-positive oropharyngeal squamous cell carcinoma.
- Conditions
- Oropharynx Cancer, Oropharynx Cancer, Metastatic, Oropharynx Cancer, Recurrent, Oropharyngeal Carcinoma
- Trial name
- NCT06592716
- Testing
- Liquid biopsy
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV
Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma
The purpose of this research study is to investigate the relationship between vascular habitats and treatment response AND to investigate the potential utility of dynamic contrast enhanced (DCE)-MRI derived parameters in…
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (OPSCC), HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- OPSCC (NCT07797738)
- Testing
- MRI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Oropharynx Cancer, Stage I
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable).
- Trial name
- NCT06254911
- Testing
- Atezolizumab, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for…
- Trial name
- NCT07844551
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab, Cisplatin
- Volunteers
- 40 people
- Sponsor
- Huashan Hospital
Carcinoma, Squamous Cell, Head and Neck Neoplasms
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
The primary objective of this study is to evaluate whether genomic based risk-stratification can be used in deciding whether to de-intensify in patients with Human Papillomavirus (HPV)-associated Oropharyngeal Squamous Cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT03077243
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Squamous Cell Carcinoma, Human Papilloma Virus (HPV)
Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC).
- Conditions
- Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- Trial name
- NCT07513389
- Testing
- Active Surveillance With ctHPVDNA (NavDx®)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
HPV-positive Oropharyngeal Squamous Cell Carcinoma
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery…
- Trial name
- NCT05419089
- Testing
- Robotic surgery
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to…
- Trial name
- NCT07812467
- Testing
- Rimegepant, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
OPSCC, Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma
HPV-associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a type of cancer that affects parts of the throat, like the tonsils and the base of the tongue.
- Conditions
- OPSCC, Oropharyngeal Squamous Cell Carcinoma (SCC), HPV Associated Cancers
- Trial name
- NCT06759155
- Testing
- de-intensified radiation
- Volunteers
- 20 people
- Sponsor
- University of Vermont Medical Center
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
This clinical trial will evaluate a new combination of treatments for Oropharyngeal Squamous Cell cancers (OPSCC), and compare it to the current standard of care (concurrent, platinum-based chemoradiotherapy).
- Trial name
- NCT03715946
- Testing
- Nivolumab Injection, Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Robert L. Ferris, MD, PhD
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital